$IMNN
Imunon, Inc. Stock $imnn

$imnn Overview Financials Valuation SEC Filings Company Website

2025 Q1 Form 10-K Financial Statement

#000149315225008460 Filed on February 27, 2025

Income Statement

Concept	2025 Q1	2024 Q4	2024
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development			$11.64M
YoY Change			3.12%
% of Gross Profit
Depreciation & Amortization			$240.2K
YoY Change			-3.22%
% of Gross Profit
Operating Expenses			$19.13M
YoY Change			-9.02%
Operating Profit			-$19.13M
YoY Change			-9.02%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net			$512.2K
YoY Change			117.9%
Pretax Income			-$18.62M
YoY Change			-10.46%
Income Tax
% Of Pretax Income
Net Earnings			-$18.60M
YoY Change			-4.62%
Net Earnings / Revenue
Basic Earnings Per Share			-$1.62
Diluted Earnings Per Share			-$1.62
COMMON SHARES
Basic Shares Outstanding	14.62M shares	14.50M shares	11.51M shares
Diluted Shares Outstanding			11.51M shares

Balance Sheet

Concept	2025 Q1	2024 Q4	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments		$5.873M
YoY Change		-62.58%
Cash & Equivalents		$5.873M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets		$8.009M
YoY Change		-56.09%
LONG-TERM ASSETS
Property, Plant & Equipment		$541.3K
YoY Change		-28.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$1.167M
YoY Change		-60.1%
Total Long-Term Assets		$1.708M
YoY Change		-53.54%
TOTAL ASSETS
Total Short-Term Assets		$8.009M
Total Long-Term Assets		$1.708M
Total Assets		$9.717M
YoY Change		-55.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses		$3.034M
YoY Change		-10.52%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$4.786M
YoY Change		-35.24%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$4.786M
Total Long-Term Liabilities
Total Liabilities		$5.473M
YoY Change		-35.84%
SHAREHOLDERS EQUITY
Retained Earnings		-$407.0M
YoY Change		4.9%
Common Stock		$145.0K
YoY Change		54.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$85.19K
YoY Change		0.0%
Treasury Stock Shares
Shareholders Equity		$4.244M
YoY Change
Total Liabilities & Shareholders Equity		$9.717M
YoY Change		-55.67%

Cashflow Statement

Concept	2025 Q1	2024 Q4	2024
OPERATING ACTIVITIES
Net Income			-$18.60M
YoY Change			-4.62%
Depreciation, Depletion And Amortization			$240.2K
YoY Change			-3.22%
Cash From Operating Activities			-$18.90M
YoY Change			-0.53%
INVESTING ACTIVITIES
Capital Expenditures			$29.54K
YoY Change			-93.46%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			$9.829M
YoY Change			-10.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$9.060M
YoY Change			225.75%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			$9.060M
YoY Change			-349.01%
NET CHANGE
Cash From Operating Activities			-$18.90M
Cash From Investing Activities			$9.829M
Cash From Financing Activities			$9.060M
Net Change In Cash			$34.20K
YoY Change			-100.29%
FREE CASH FLOW
Cash From Operating Activities			-$18.90M
Capital Expenditures			$29.54K
Free Cash Flow			-$18.93M
YoY Change			-2.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0000749647
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-19514977	usd
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity Registrant Name EntityRegistrantName	IMUNON, INC.
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	29327866	usd
CY2024	dei	Trading Symbol TradingSymbol	IMNN
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent		usd
CY2024Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
CY2024Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		usd
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2024	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
CY2024	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax		usd
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2024	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs		usd
CY2024	IMNN	Amortization Of Deferred Finance Charges And Debt Discount Associated With Note Payable AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable		usd
CY2024	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable		usd
CY2024	IMNN	Paymentoff Of Loan And Accrued Endofterm Fees PaymentoffOfLoanAndAccruedEndoftermFees		usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024	IMNN	Recognition Of Right Use Asset And Liability RecognitionOfRightUseAssetAndLiability		usd
CY2024Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent		usd
CY2024Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Within Three Months Amortized Cost DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost		usd
CY2024Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Within Three Months Fair Value DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue		usd
CY2024Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Between Three And Twelve Months Amortized Cost DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsAmortizedCost		usd
CY2024Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Between Three And Twelve Months Fair Value DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsFairValue		usd
CY2024Q4	IMNN	Available For Sale Debt Securities Amortized Cost Basis Current AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent		usd
CY2024Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate		usd
CY2024Q4	IMNN	Available For Sale Securities Unrealized Loss Fair Value AvailableForSaleSecuritiesUnrealizedLossFairValue		usd
CY2024Q4	IMNN	Available For Sale Securities Unrealized Holding Gain Loss Less Than Twelve Months AvailableForSaleSecuritiesUnrealizedHoldingGainLossLessThanTwelveMonths		usd
CY2024	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2024	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2024	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2024	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate		pure
CY2023	IMNN	Effective Income Tax Rate Reconciliation Deferred Statutory Rate EffectiveIncomeTaxRateReconciliationDeferredStatutoryRate		pure
CY2023	IMNN	Effective Income Tax Rate Reconciliation Sale And Expiration EffectiveIncomeTaxRateReconciliationSaleAndExpiration		pure
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2024Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2024Q4	IMNN	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-12-31
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Entity File Number EntityFileNumber	001-15911
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-1256615
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	997 LENOX DRIVE
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	SUITE 100
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	LAWRENCEVILLE
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08648
CY2024	dei	City Area Code CityAreaCode	(609)
CY2024	dei	Local Phone Number LocalPhoneNumber	896-9100
CY2024	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01 Per Share
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Public Float EntityPublicFloat	10800000	usd
CY2025Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14620732	shares
CY2024	cyd	Cybersecurity Risk Management Processes Integrated Flag CybersecurityRiskManagementProcessesIntegratedFlag	true
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	72974615	usd
CY2024	cyd	Cybersecurity Risk Management Processes Integrated Flag CybersecurityRiskManagementProcessesIntegratedFlag	true
CY2024	cyd	Cybersecurity Risk Management Third Party Engaged Flag CybersecurityRiskManagementThirdPartyEngagedFlag	true
CY2024	cyd	Cybersecurity Risk Third Party Oversight And Identification Processes Flag CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag	true
CY2024	cyd	Cybersecurity Risk Materially Affected Or Reasonably Likely To Materially Affect Registrant Flag CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag	false
CY2024	cyd	Cybersecurity Risk Management Positions Or Committees Responsible Flag CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag	true
CY2024	cyd	Cybersecurity Risk Management Positions Or Committees Responsible Flag CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag	true
CY2024	cyd	Cybersecurity Risk Management Positions Or Committees Responsible Report To Board Flag CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag	true
CY2024	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024	IMNN	Rule10b51 Arr Modified Flag Rule10b51ArrModifiedFlag	false
CY2024	IMNN	Non Rule10b51 Arr Modified Flag NonRule10b51ArrModifiedFlag	false
CY2024	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2024	dei	Auditor Location AuditorLocation	East Brunswick, New Jersey
CY2024	dei	Auditor Firm AuditorFirmId	100
CY2024Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5872767	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5838566	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	9857087	usd
CY2024Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	2136192	usd
CY2023Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	2545051	usd
CY2024Q4	us-gaap	Assets Current AssetsCurrent	8008959	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	18240704	usd
CY2024Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	541272	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	751906	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1280385	usd
CY2024Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1117133	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1595074	usd
CY2024Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	50000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	50000	usd
CY2024Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1167133	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2925459	usd
CY2024Q4	us-gaap	Assets Assets	9717364	usd
CY2023Q4	us-gaap	Assets Assets	21918069	usd
CY2024Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1300026	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3515192	usd
CY2024Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3033747	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3390521	usd
CY2024Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	452358	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	485421	usd
CY2024Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4786131	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7391134	usd
CY2024Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	686935	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1139293	usd
CY2024Q4	us-gaap	Liabilities Liabilities	5473066	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8530427	usd
CY2024Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2024Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	112500000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	112500000	shares
CY2024Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14500707	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9399811	shares
CY2024Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14500685	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9399789	shares
CY2024Q4	us-gaap	Common Stock Value CommonStockValue	145007	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	93998	usd
CY2024Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	410987523	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	401500838	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	60796	usd
CY2024Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-406803044	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-388182802	usd
CY2024Q4	us-gaap	Stockholders Equity Before Treasury Stock StockholdersEquityBeforeTreasuryStock	4329486	usd
CY2023Q4	us-gaap	Stockholders Equity Before Treasury Stock StockholdersEquityBeforeTreasuryStock	13472830	usd
CY2024Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	22	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	22	shares
CY2024Q4	us-gaap	Treasury Stock Value TreasuryStockValue	85188	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	85188	usd
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	4244298	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13387642	usd
CY2024Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9717364	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21918069	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11639411	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11287691	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7493035	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9742739	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	19132446	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	21030430	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-19132446	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-21030430	usd
CY2024	us-gaap	Investment Income Net InvestmentIncomeNet	512204	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	1157625	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-329158	usd
CY2023	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	197080	usd
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	396319	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	512204	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	235068	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18620242	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20795362	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1280385	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-18620242	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-19514977	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.62
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.62
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.16
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.16
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11508159	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11508159	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9045320	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9045320	shares
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	34302	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-18620242	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-19514977	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18620242	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19480675	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-18620242	usd
CY2024	us-gaap	Depreciation Depreciation	240175	usd
CY2023	us-gaap	Depreciation Depreciation	248154	usd
CY2024	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	477941	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	471851	usd
CY2024	us-gaap	Gain Loss On Investments GainLossOnInvestments	61983	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-34302	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	477256	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	759013	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1280385	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	286641	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-329158	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	375000	usd
CY2023	IMNN	Amortization Of Deferred Finance Charges And Debt Discount Associated With Note Payable AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable	55122	usd
CY2023	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	-68136	usd
CY2024	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-408859	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	141619	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3057361	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1992929	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18854970	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19022148	usd
CY2024	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	57174	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	13541806	usd
CY2024	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	9915448	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	25000000	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29541	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	451759	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9828733	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11006435	usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9060438	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2781438	usd
CY2023	IMNN	Paymentoff Of Loan And Accrued Endofterm Fees PaymentoffOfLoanAndAccruedEndoftermFees	6420000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9060438	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3638562	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	34201	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11654275	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5838566	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17492841	usd
CY2024Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5872767	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5838566	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	179542	usd
CY2023	IMNN	Recognition Of Right Use Asset And Liability RecognitionOfRightUseAssetAndLiability	1911049	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13387642	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-18620242	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9060438	usd
CY2024	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	121	usd
CY2024	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-60796	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	477135	usd
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	4244298	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	29327866	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-19514977	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2781438	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	595	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	34302	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	758418	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13387642	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13387642	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_z1OUXqQnRFab" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_zwIEi2FD2nra">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of expenses during the reporting period. Actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	240000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	248000	usd
CY2024	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2024	IMNN	Number Of Shares Of Common Stock Issuable Upon Exercise Of Warrants And Equity Awards NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards	6840633	shares
CY2023	IMNN	Number Of Shares Of Common Stock Issuable Upon Exercise Of Warrants And Equity Awards NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards	1255642	shares
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-18600000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18900000	usd
CY2024Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-407000000	usd
CY2024Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	5900000	usd
CY2024	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	9857087	usd
CY2023Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Within Three Months Amortized Cost DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost	2467518	usd
CY2023Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Within Three Months Fair Value DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue	2490775	usd
CY2023Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Between Three And Twelve Months Amortized Cost DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsAmortizedCost	7328773	usd
CY2023Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Between Three And Twelve Months Fair Value DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsFairValue	7366312	usd
CY2023Q4	IMNN	Available For Sale Debt Securities Amortized Cost Basis Current AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent	9796291	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	9857087	usd
CY2023Q4	IMNN	Available For Sale Securities Unrealized Loss Fair Value AvailableForSaleSecuritiesUnrealizedLossFairValue	9857087	usd
CY2023Q4	IMNN	Available For Sale Securities Unrealized Holding Gain Loss Less Than Twelve Months AvailableForSaleSecuritiesUnrealizedHoldingGainLossLessThanTwelveMonths	60796	usd
CY2024	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	450221	usd
CY2023	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	725824	usd
CY2024	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	61983	usd
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	431801	usd
CY2024	us-gaap	Investment Income Net InvestmentIncomeNet	512204	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	1157625	usd
CY2024Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1737567	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2854178	usd
CY2024Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1196295	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2102272	usd
CY2024Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	541272	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	751906	usd
CY2024Q4	us-gaap	Contractual Obligation ContractualObligation	1048036	usd
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	1442659	usd
CY2024Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1945111	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1693383	usd
CY2024Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	20600	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	234479	usd
CY2024Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20000	usd
CY2024Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3033747	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3390521	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1280385	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1280385	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0840	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.071	pure
CY2024	IMNN	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0274	pure
CY2023	IMNN	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.031	pure
CY2024	IMNN	Effective Income Tax Rate Reconciliation Time Up EffectiveIncomeTaxRateReconciliationTimeUp	-0.0007	pure
CY2023	IMNN	Effective Income Tax Rate Reconciliation Time Up EffectiveIncomeTaxRateReconciliationTimeUp	-1.050	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0011	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.029	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0057	pure
CY2024	IMNN	Effective Income Tax Rate Reconciliation Deferred Statutory Rate EffectiveIncomeTaxRateReconciliationDeferredStatutoryRate	-0.0075	pure
CY2024	IMNN	Effective Income Tax Rate Reconciliation Sale And Expiration EffectiveIncomeTaxRateReconciliationSaleAndExpiration	-0.1751	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0901	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.890	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.061	pure
CY2024Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	66141490	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	67310000	usd
CY2024Q4	IMNN	Deferred Tax Assets Legal Act DeferredTaxAssetsLegalAct	6482099	usd
CY2023Q4	IMNN	Deferred Tax Assets Legal Act DeferredTaxAssetsLegalAct	4929000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2010744	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2016000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	74634333	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	74255000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	74634333	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	72974615	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1280385	usd
CY2024Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2024	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2024	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	Expenses incurred in connection with R&E activities in the US must be amortized over a 5-year period if incurred, and R&E expenses incurred outside the US must be amortized over a 15-year period. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2024, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&E capitalization and amortization to require it to pay cash taxes now or in the near future. The Company’s income tax returns for 2020 to 2023 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years.
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	75000000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	75000000	usd
CY2024Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5500000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	69650	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.92
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	22100	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.92
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	59450	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.91
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	200	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	4.60
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	32100	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.23
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1280385	usd
CY2024Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2024	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2024	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	Expenses incurred in connection with R&E activities in the US must be amortized over a 5-year period if incurred, and R&E expenses incurred outside the US must be amortized over a 15-year period. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2024, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&E capitalization and amortization to require it to pay cash taxes now or in the near future. The Company’s income tax returns for 2020 to 2023 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years.
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	75000000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	75000000	usd
CY2024Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5500000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	69650	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.92
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	22100	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.92
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	59450	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.91
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	200	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	4.60
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	32100	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.23
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	39700	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.99
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	12100	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.84
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	20000	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0.88
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	39700	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.99
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1645873	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	907723	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	39700	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.99
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	12100	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.84
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	20000	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0.88
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	39700	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.99
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1645873	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	907723	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0372	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0450	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0339	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0481	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.017	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.158	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.000	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.136	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2024Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	500000	usd
CY2024	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	168519	shares
CY2022Q4	IMNN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	19.78
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5000000	shares
CY2024	IMNN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Grants In Perios Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriosWeightedAverageExercisePrice	2.00
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	8459	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	37.29
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	160060	shares
CY2023Q4	IMNN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	18.86
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5000000	shares
CY2024	IMNN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Grants In Perios Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriosWeightedAverageExercisePrice	2.00
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	5000	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	11.85
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5155060	shares
CY2024Q4	IMNN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	2.51
CY2024	IMNN	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0372	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0450	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0339	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0481	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.017	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.158	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.000	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.136	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2024Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	500000	usd
CY2024	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	168519	shares
CY2022Q4	IMNN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	19.78
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5000000	shares
CY2024	IMNN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Grants In Perios Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriosWeightedAverageExercisePrice	2.00
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	8459	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	37.29
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	160060	shares
CY2023Q4	IMNN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	18.86
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5000000	shares
CY2024	IMNN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Grants In Perios Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionGrantsInPeriosWeightedAverageExercisePrice	2.00
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	5000	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	11.85
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5155060	shares
CY2024Q4	IMNN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	2.51
CY2024	IMNN	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y
CY2024	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03	pure
CY2024	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	62000	usd
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	142000	usd
CY2024	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03	pure
CY2024	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	62000	usd
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	142000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P24M
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	543009	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	362976	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	370235	usd
CY2024Q4	IMNN	Lessee Operating Lease Liability Payments Due Year Four And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter	30904	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1307124	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	167831	usd
CY2024Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1139293	usd
CY2024Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2024Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0998	pure
CY2024Q4	IMNN	Operating Leases Incremental Borrowing Rate OperatingLeasesIncrementalBorrowingRate	0.0998	pure
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	652166	usd
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	659646	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	646633	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	644593	usd
CY2024	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	478000	usd
CY2023	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	472000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P24M
CY2023Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P60M
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	543009	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	362976	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	370235	usd
CY2024Q4	IMNN	Lessee Operating Lease Liability Payments Due Year Four And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter	30904	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1307124	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	167831	usd
CY2024Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1139293	usd
CY2024Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2024Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0998	pure
CY2024Q4	IMNN	Operating Leases Incremental Borrowing Rate OperatingLeasesIncrementalBorrowingRate	0.0998	pure
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	652166	usd
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	659646	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	646633	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	644593	usd
CY2024	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	478000	usd
CY2023	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	472000	usd

Files In Submission

Name	View Source	Status
0001493152-25-008460-index-headers.html	Edgar Link	pending
0001493152-25-008460-index.html	Edgar Link	pending
0001493152-25-008460.txt	Edgar Link	pending
0001493152-25-008460-xbrl.zip	Edgar Link	pending
ex19.htm	Edgar Link	pending
ex19_001.jpg	Edgar Link	pending
ex19_002.jpg	Edgar Link	pending
ex19_003.jpg	Edgar Link	pending
ex19_004.jpg	Edgar Link	pending
ex19_005.jpg	Edgar Link	pending
ex19_006.jpg	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-7.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
imnn-20241231.xsd	Edgar Link	pending
imnn-20241231_def.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
imnn-20241231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
imnn-20241231_cal.xml	Edgar Link	unprocessable
imnn-20241231_lab.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IMNN
Imunon, Inc. Stock $imnn

2025 Q1 Form 10-K Financial Statement

#000149315225008460 Filed on February 27, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMNN Imunon, Inc. Stock $imnn

2025 Q1 Form 10-K Financial Statement

#000149315225008460 Filed on February 27, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMNN
Imunon, Inc. Stock $imnn